银屑病患者妊娠前后生物制剂暴露的系统综述与荟萃分析
该系统综述与荟萃分析纳入51项观察性研究、739例妊娠期暴露于获批银屑病生物制剂的妊娠,评估流产、 elective流产及先天畸形的合并患病率。结果显示流产患病率15.3%(95%CI 12.7-18.0),elective流产10.8%(95%CI 7.7-14.3),活产儿先天畸形约3.0%(95%CI 1.6-4.8),与一般人群相似,提示妊娠期和/或受孕期暴露于银屑病生物制剂似乎不增加流产或先天畸形风险。
要点
- 纳入51项观察性研究、739例妊娠期暴露于获批银屑病生物制剂的妊娠。
- 流产患病率15.3%(95%CI 12.7-18.0),elective流产10.8%(95%CI 7.7-14.3)。
- 活产儿先天畸形约3.0%(95%CI 1.6-4.8),与一般人群相似。
核心结论
- 妊娠期和/或受孕期暴露于银屑病生物制剂似乎不增加流产/堕胎或先天畸形风险,与一般人群相似。
- 结果提示生物制剂药物安全,对胎儿/新生儿构成可接受的风险。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Scopus和Web of Science数据库至2022年4月14日,无样本量或发表时间限制。
- 遵循PRISMA指南,由两名评价者评估报告妊娠结局的随机对照试验和非随机研究。
- 纳入51项观察性研究,涉及739例妊娠期暴露于获批银屑病生物制剂的妊娠。
- 排除聚焦风湿病或胃肠病免疫介导炎症性疾病的研究。
- 无论数据异质性如何,均使用随机效应模型合并患病率估计。
主要发现
- 给药大多(70.4%)限于妊娠早期,最常用药物为乌司奴单抗(36.0%)。
- 流产估计患病率为15.3%(95%CI 12.7-18.0),elective流产为10.8%(95%CI 7.7-14.3)。
- 妊娠期暴露于生物制剂的活产儿中先天畸形发生率约3.0%(95%CI 1.6-4.8)。
关键数值与推荐
- 流产患病率15.3%(95%CI 12.7-18.0)。
- elective流产患病率10.8%(95%CI 7.7-14.3)。
- 活产儿先天畸形患病率约3.0%(95%CI 1.6-4.8)。
临床怎么用
- 妊娠期和/或受孕期暴露于获批银屑病生物制剂似乎不增加流产/堕胎或先天畸形风险,与一般人群相似。
- 结果提示生物制剂药物安全,对胎儿/新生儿构成可接受的风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biologicals have transformed the management of severe disease phenotypes in psoriasis and are often prescribed in women of childbearing age. However, information on safety of biologicals in pregnancy are lacking. We conducted a systematic review and meta-analysis aimed to describe the characteristics and pregnancy outcomes in women with psoriasis exposed to biologics within 3 months before or during pregnancy, and to estimate the pooled prevalence of spontaneous, elective and total abortions, and congenital malformations in their newborns. Bibliographic searches were performed in the PubMed, Embase, Scopus and Web of Science databases up to 14 April 2022. No restrictions on sample size or publication date were applied. Review performance complied with PRISMA guidelines, and two reviewers assessed randomized controlled trials and nonrandomized studies reporting pregnancy outcomes in women exposed to biologics indicated for psoriasis during the pre-gestational and/or gestational period. Studies focusing on rheumatologic or gastroenterological immune-mediated inflammatory diseases were excluded. Regardless of data heterogeneity, a random-effects model was used to pool prevalence estimates. We included 51 observational studies, involving 739 pregnancies exposed to approved biologics for psoriasis. Administration was mostly (70.4%) limited to the first trimester, and the most common drug was ustekinumab (36.0%). The estimated prevalence of miscarriage was 15.3% (95% confidence interval [CI] 12.7-18.0) and elective abortions, 10.8% (95% CI 7.7-14.3). Congenital malformations occurred in about 3.0% (95% CI 1.6-4.8) of live births exposed to biologics during pregnancy. Altogether, exposure to biologics for psoriasis during pregnancy and/or conception does not seem to be associated with an increased risk of miscarriage/abortion or congenital malformations, showing similar rates to the general population. These results suggest that biologic drugs are safe and pose an acceptable risk to the foetuses/neonates.
引用
- Sánchez-García V, Hernández-Quiles R, de-Miguel-Balsa E, et al. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023. PMID: 37262303. doi:10.1111/jdv.19238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。